Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03661437 · ClinicalTrials.gov registry record · Early Phase 1
Systemic Light Exposure in Preventing Frailty in Older Patients With Prostate Cancer on Hormonal Therapy
A Early Phase 1 study of Prostate Carcinoma, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT03661437: Completed Early Phase 1 study of Prostate Carcinoma, sponsored by City of Hope Medical Center.
NCT03661437 is a Early Phase 1 study of Prostate Carcinoma that has completed, run by City of Hope Medical Center. The registered enrollment target is 33 participants, below the 1,501-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03661437, a Early Phase 1 study of Prostate Carcinoma, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot trial studies how well systemic light exposure works in preventing frailty in older patients with prostate cancer on hormonal therapy. Hormone therapy causes many symptoms of frailty in older men including fatigue, slower time to walk a specified distance, reduced activity levels, loss of lean muscle, and muscle weakness. It is not yet known if systemic light exposure may reduce frailty in older prostate cancer patients.
Primary Outcome
Will be assessed using Short Physical Performance Battery (SPPB). Will be evaluated using a repeated measures mixed linear model.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- DEVICE Actigraph
- PROCEDURE Systematic Light Exposure
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2018-09-24 |
| Est. Completion | 2025-03-24 |
| Phase | Early Phase 1 |
What the finished NCT03661437 record still lists
NCT03661437 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 1,501-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Prostate Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Questionnaire Administration is the first listed.
NCT03661437 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03661437 about?
NCT03661437 is a clinical study titled "Systemic Light Exposure in Preventing Frailty in Older Patients With Prostate Cancer on Hormonal Therapy". This pilot trial studies how well systemic light exposure works in preventing frailty in older patients with prostate cancer on hormonal therapy. Hormone therapy causes many symptoms of frailty in older men including fatigue, slower time to walk a specified distance, reduced activity levels, loss of...
What is the current status of trial NCT03661437?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 33 participants. The study started on 2018-09-24. Estimated completion is 2025-03-24.
What conditions does trial NCT03661437 study?
This clinical trial studies the following conditions: Prostate Carcinoma.
What interventions are being tested in trial NCT03661437?
The interventions under investigation include: Questionnaire Administration (OTHER), Actigraph (DEVICE), Systematic Light Exposure (PROCEDURE).
Who is sponsoring clinical trial NCT03661437?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03661437 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03661437's enrollment target sits among peer trials
33 46th of 59 higher than 13 of 59 other Prostate Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
RECRUITING · Early Phase 1
-
Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial
RECRUITING · Early Phase 1
-
Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy
ACTIVE NOT RECRUITING · Early Phase 1
-
An Investigational Scan (MRI With Dixon Based Sequences) in Detecting Prostate Cancer
ACTIVE NOT RECRUITING · Early Phase 1
-
Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer
COMPLETED · Early Phase 1
-
Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI